Eli Lilly CDR (CAD Hedged)
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Enzastaurin for Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 28
- Registration Number
- NCT00192114
- Locations
- πΈπͺ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden
Long-Term, Open Label Atomoxetine Study
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-01-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1553
- Registration Number
- NCT00190684
- Locations
- π¬π§
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, South Yorkshire, United Kingdom
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-11-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT00191295
- Locations
- π―π΅
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wakayama, Japan
Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)
- Conditions
- Urinary Incontinence, Stress
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-01-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 500
- Registration Number
- NCT00190827
- Locations
- πͺπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 OR 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician, Barcelona, Spain
π¨π¦For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 or 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician, Quebec, Canada
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT00162318
- Locations
- πΊπΈ
Local Institution, Pittsburgh, Pennsylvania, United States
A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2015-10-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT00162110
- Locations
- πΊπΈ
Local Institution, Cincinnati, Ohio, United States
Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD
- Conditions
- Diabetes MellitusAsthmaPulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Human Insulin Inhalation PowderDrug: injected insulin
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 299
- Registration Number
- NCT00157339
- Locations
- πΉπ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand
Tadalafil in Subjects With Mild to Moderate Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-10-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 180
- Registration Number
- NCT00157326
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bothell, Washington, United States
Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 257
- Registration Number
- NCT00149214
- Locations
- πͺπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain
A Study in People With High Cholesterol
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2007-04-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT00133380
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingsport, Tennessee, United States